No article text was recorded for this version.
socioeconomic treatment barriers
Version 1 of 116 papers27 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for people with ultra-high viral load of HIV-1: a retrospective real-world cohort study
- Blog: Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients
- Blog: Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006
- Blog: Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients Managed at Chinese Academic Centers in the Rituximab Era: A Real-World Study
- Blog: MANEJO CLÍNICO DA ASMA EM ADULTOS: TERAPIAS INOVADORAS E ABORDAGENS PERSONALIZADAS
- Blog: Consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology on the management of muscle-invasive and advanced urothelial carcinoma
- Blog: A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)
- Blog: Management strategy in patient with familial gigantiform cementoma
- Blog: A case of primary non-small cell lung cancer with synchronous small cell lung cancer
- Blog: Best practice advice for asthma exacerbation prevention and management in primary care: an international expert consensus
- Blog: Open challenges in developing digital therapeutics in the United States
- Blog: Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM
- Blog: Treatment Trade‐Offs and Choices for Femoral Fractures: A Systematic Review and Meta‐Analysis
- Blog: Regulatory and Quality Compliance of Oncology Products – A Global perspective
- Blog: Treatment of pulmonary arterial hypertension in congenital heart disease in Singapore versus the Netherlands: age exceeds ethnicity in influencing clinical outcome
- Blog: Consumption and expenditure on fidaxomicin and oral vancomycin for Clostridioides difficile infection: A 12-year longitudinal study of 43 countries and regions
History & citation
Current · Permanent link
- This direction split from Bridging the Clinical Innovation and Economic Accessibility Gap (100% overlap)
Cite this direction
Latest version (a living page):
@misc{lacuna_socioeconomic_treatment_barriers_a3bbea49,
title = {socioeconomic treatment barriers},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/socioeconomic-treatment-barriers/rdr_a3bbea49dd51437b8fd03cdf79381882},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}This exact version (version 1, frozen text):
@misc{lacuna_socioeconomic_treatment_barriers_a3bbea49_v1,
title = {socioeconomic treatment barriers},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/socioeconomic-treatment-barriers/rdr_a3bbea49dd51437b8fd03cdf79381882/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}